The Science
A new way to think about building cancer drugs
innovative macrocycle drug conjugates
Macrocycles are biologically inspired ring-shaped scaffolds.
Our Macrocycle Drug Conjugates (MDCs) enable selective tumor penetration and prolong retention.
Our lead candidate, NOVO-111, has shown remarkable preclinical results and is on track for clinical trials.
multi-modal platform technology
New IP for each asset. For illustrative purposes only.
Clinical Validation
Platform leverages a clinically validated macrocycle used in >1000 patients creating confirmed regulatory and clinical efficiencies.
Improved Therapeutic Index
Concentrating drug activity where it’s needed (e.g., tumor tissue) while limiting systemic exposure.
Market Expansion
Enable novel drug conjugates that do not rely on traditional antibody targeting. Offers predictable pharmacokinetics and stability, supporting more durable responses.
NOVO-111
Lead clinical candidate: NOVO-111
NOVO-111 is INNOVOTEX’s lead development candidate and the first demonstration of the broader MDC platform. Being developed initially for colorectal cancer, NOVO-111 combines a macrocycle designed for tumor localization and retention with a platinum-based therapeutic payload related to oxaliplatin.
PROBLEM
Oncology Drugs Reach Tumors, But Aren’t Retained Long Enough To Drive Durable Responses.
- PK/BD failures: <0.5% of the ADC accumulates in the tumor
- Drives significant off-target toxicities
- Incomplete responses
- Resistance
- Narrow therapeutic windows
SOLUTION
Macrocycle Drug Conjugates (MDCs): Engineered For Selective Tumor Retention.
- Antigen independent: >10% retention in the tumor
- Selective tumor retention signature
- Sustained intracellular exposure leads to enhanced durability and efficacy in animal studies
Pipeline
Multi-modal platform
INNOVOTEX is applying the MDC platform across multiple therapeutic payloads and potential oncology applications, creating opportunities to develop differentiated assets beyond its lead candidate, NOVO-111.
Multi-Modal Platform
For MDC Discovery and Selection
MDC Payload
Proposed Indication
Discovery
POC
IND-enabling
Rights
Oxaliplatin
DNA Damage
Solid Tumors
E.g., CRC, NSCLC, Ovarian
NOVO-111
COMBINATION WITH SOC
Global
Phototherapy
Breast, Melanoma
NOVO-112
Global
Dual Payload
TBD
NOVO-113
Filed
Radionuclide
TBD
NOVO-114
TBD
Potential Candidate Expansion
Macrocycle + External Validated Payloads
Beyond its current programs, INNOVOTEX is exploring the potential to combine macrocycles with externally validated payloads to support additional therapeutic candidates and future asset development.
about
our mission
is to improve patient outcomes through innovative macrocycle-mediated targeted delivery systems.
Leadership Team
DR. KRYSTLE KAROSCIK
Co-founder, CEO
& Board Director
DR. JONATHAN ARAMBULA
Co-founder, CTO &
Executive Chairman
JAMES HUSSEY
Executive Vice Chairman
Capital Formation, Corporate
Strategy, & Alliance Management
news
latest news
- All
- Company News
- Regulatory Updates
- White Papers
Reengineering a Global Standard of Care
Colorectal cancer (CRC) represents a distinctive therapeutic and commercial opportunity: a large global oncology market in which one of the...
NOVO-111 in Colorectal Cancer
Colorectal cancer (CRC) remains one of the most consequential malignancies worldwide, with approximately 1.9 million new cases and more than...
Macrocycle Drug Conjugates: Engineering the Therapeutic Index
The evolution of precision oncology has largely been defined by increasingly selective therapeutic strategies....
contact
contact us
We welcome conversations with investors, pharmaceutical partners and others interested in the future of Macrocycle Drug Conjugates.